The abstract is read at the publisher; the summary is JClub's.
Platinum-based chemotherapy combined with a PD-1 inhibitor is recommended as preferred first-line systemic therapy for medically fit patients with recurrent and/or metastatic nasopharyngeal carcinoma.
- Why it matters: Clinicians need evidence-based guidance for choosing first- and later-line systemic therapy, maintenance, and salvage local treatments in recurrent and/or metastatic NPC.
- What they did: CSCO and ASCO convened a multidisciplinary panel that reviewed randomized trials, meta-analyses, systematic reviews, and other studies, weighing overall and progression-free survival, response, toxicity, and quality of life.
- The result: The guideline supports maintenance PD-1 inhibition for up to 2 years after disease control, plus locoregional consolidation or salvage surgery/re-irradiation for selected patients with appropriate disease patterns.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.